{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:15:10Z","timestamp":1785762910500,"version":"3.56.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"VLAIO Baekeland mandate","award":["HBC.2019.2575"],"award-info":[{"award-number":["HBC.2019.2575"]}]},{"DOI":"10.13039\/100012331","name":"Flanders Innovation & Entrepreneurship","doi-asserted-by":"crossref","award":["030383"],"award-info":[{"award-number":["030383"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-024-01866-0","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:01:46Z","timestamp":1728550906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A pathogenic mutation in the ALS\/FTD gene VCP induces mitochondrial hypermetabolism by modulating the permeability transition pore"],"prefix":"10.1186","volume":"12","author":[{"given":"Silke","family":"Vanderhaeghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Prerad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Kumar","family":"Tharkeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elien","family":"Goethals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katlijn","family":"Vints","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Scheveneels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Debroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Princen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fivaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Van Den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"1866_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.gene.2016.02.042","volume":"583","author":"D Xia","year":"2016","unstructured":"Xia D, Tang WK, Ye Y (2016) Structure and function of the AAA+ ATPase p97\/Cdc48p. Gene 583:64\u201377","journal-title":"Gene"},{"key":"1866_CR2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/j.1460-2075.1990.tb08300.x","volume":"9","author":"JM Peters","year":"1990","unstructured":"Peters JM, Walsh MJ, Franke WW (1990) An abundant and ubiquitous homo-oligomeric ring-shaped ATPase particle related to the putative vesicle fusion proteins Sec18p and NSF. EMBO J 9:1757\u20131767","journal-title":"EMBO J"},{"key":"1866_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2008-9-4-216","volume":"9","author":"J Snider","year":"2008","unstructured":"Snider J, Thibault G, Houry WA (2008) The AAA+ superfamily of functionally diverse proteins. Genome Biol 9:1\u20138","journal-title":"Genome Biol"},{"key":"1866_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-023-00639-y","volume":"18","author":"S Chu","year":"2023","unstructured":"Chu S, Xie X, Payan C, Stochaj U (2023) Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases. Mol Neurodegener 18:52","journal-title":"Mol Neurodegener"},{"key":"1866_CR5","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.febslet.2015.08.028","volume":"589","author":"A Buchberger","year":"2015","unstructured":"Buchberger A, Schindelin H, H\u00e4nzelmann P (2015) Control of p97 function by cofactor binding. FEBS Lett 589:2578\u20132589","journal-title":"FEBS Lett"},{"key":"1866_CR6","doi-asserted-by":"crossref","unstructured":"Braxton JR, Southworth DR (2023) Structural insights of the p97\/VCP AAA+ ATPase: how adapter interactions coordinate diverse cellular functionality. J Biol Chem 299:105182","DOI":"10.1016\/j.jbc.2023.105182"},{"key":"1866_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.tibs.2006.11.005","volume":"32","author":"S Jentsch","year":"2007","unstructured":"Jentsch S, Rumpf S (2007) Cdc48 (p97): a \u201cmolecular gearbox\u201d in the ubiquitin pathway? Trends Biochem Sci 32:6\u201311","journal-title":"Trends Biochem Sci"},{"key":"1866_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.molcel.2017.10.028","volume":"69","author":"J van den Boom","year":"2018","unstructured":"van den Boom J, Meyer H (2018) VCP\/p97-mediated unfolding as a principle in protein homeostasis and signaling. Mol Cell 69:182\u2013194","journal-title":"Mol Cell"},{"key":"1866_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02172-5","volume":"17","author":"M Korb","year":"2022","unstructured":"Korb M, Peck A, Alfano LN, Berger KI, James MK, Ghoshal N et al (2022) Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet J Rare Dis 17:1\u201315","journal-title":"Orphanet J Rare Dis"},{"key":"1866_CR10","doi-asserted-by":"publisher","first-page":"187.e11","DOI":"10.1016\/j.neurobiolaging.2018.06.037","volume":"72","author":"D Saracino","year":"2018","unstructured":"Saracino D, Clot F, Camuzat A, Anquetil V, Hannequin D, Guyant-Mar\u00e9chal L et al (2018) Novel VCP mutations expand the mutational spectrum of frontotemporal dementia. Neurobiol Aging 72:187.e11-187.e14","journal-title":"Neurobiol Aging"},{"key":"1866_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cge.13095","volume":"93","author":"E Al-Obeidi","year":"2018","unstructured":"Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang AK, Hermann A et al (2018) Genotype\u2013phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet 93:119\u2013125","journal-title":"Clin Genet"},{"key":"1866_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2022.105722","volume":"169","author":"MA Johnson","year":"2022","unstructured":"Johnson MA, Klickstein JA, Khanna R, Gou Y, Raman M (2022) The Cure VCP Scientific Conference 2021: molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1). Neurobiol Dis 169:1\u201311","journal-title":"Neurobiol Dis"},{"key":"1866_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature11922","volume":"495","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z et al (2013) Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495:467\u2013473","journal-title":"Nature"},{"key":"1866_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00125817-200007000-00006","volume":"2","author":"VE Kimonis","year":"2000","unstructured":"Kimonis VE, Kovach MJ, Waggoner B, Leal S, Salam A, Rimer L et al (2000) Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med 2:232\u2013241","journal-title":"Genet Med"},{"key":"1866_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cge.12000","volume":"83","author":"SG Mehta","year":"2013","unstructured":"Mehta SG, Khare M, Ramani R, Watts GDJ, Simon M, Osann KE et al (2013) Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and\/or frontotemporal dementia. Clin Genet 83:422\u2013431","journal-title":"Clin Genet"},{"key":"1866_CR16","doi-asserted-by":"publisher","first-page":"837.e7","DOI":"10.1016\/j.neurobiolaging.2011.10.006","volume":"33","author":"M Koppers","year":"2012","unstructured":"Koppers M, van Blitterswijk MM, Vlam L, Rowicka PA, van Vught PWJ, Groen EJN et al (2012) VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 33:837.e7-837.e13","journal-title":"Neurobiol Aging"},{"key":"1866_CR17","doi-asserted-by":"publisher","first-page":"2231.e1","DOI":"10.1016\/j.neurobiolaging.2012.04.005","volume":"33","author":"Y Abramzon","year":"2012","unstructured":"Abramzon Y, Johnson JO, Scholz SW, Taylor JP, Brunetti M, Calvo A et al (2012) Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 33:2231.e1-2231.e6","journal-title":"Neurobiol Aging"},{"key":"1866_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-014-0172-0","volume":"2","author":"T Ayaki","year":"2014","unstructured":"Ayaki T, Ito H, Fukushima H, Inoue T, Kondo T, Ikemoto A et al (2014) Immunoreactivity of valosin-containing protein in sporadic amyotrophic lateral sclerosis and in a case of its novel mutant. Acta Neuropathol Commun 2:1\u201314","journal-title":"Acta Neuropathol Commun"},{"key":"1866_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2022.841394","volume":"13","author":"E Scarian","year":"2022","unstructured":"Scarian E, Fiamingo G, Diamanti L, Palmieri I, Gagliardi S, Pansarasa O (2022) The role of VCP mutations in the spectrum of amyotrophic lateral sclerosis\u2014frontotemporal dementia. Front Neurol 13:1\u201315","journal-title":"Front Neurol"},{"key":"1866_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","volume":"79","author":"SC Ling","year":"2013","unstructured":"Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in als and FTD: disrupted RNA and protein homeostasis. Neuron 79:416\u2013438","journal-title":"Neuron"},{"key":"1866_CR21","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1007\/s12035-022-02934-z","volume":"59","author":"L Kirola","year":"2022","unstructured":"Kirola L, Mukherjee A, Mutsuddi M (2022) Recent updates on the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Mol Neurobiol 59:5673\u20135694","journal-title":"Mol Neurobiol"},{"key":"1866_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000443205","volume":"41","author":"K Kansal","year":"2016","unstructured":"Kansal K, Mareddy M, Sloane KL, Minc AA, Rabins PV, McGready JB et al (2016) Survival in frontotemporal dementia phenotypes: a meta-analysis. Dement Geriatr Cogn Disord 41:109\u2013122","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1866_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2010.11.036","volume":"68","author":"JO Johnson","year":"2010","unstructured":"Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ et al (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68:857\u2013864","journal-title":"Neuron"},{"key":"1866_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2022.790082","volume":"13","author":"S-Y Feng","year":"2022","unstructured":"Feng S-Y, Lin H, Che C-H, Huang H-P, Liu C-Y, Zou Z-Y (2022) Phenotype of VCP mutations in chinese amyotrophic lateral sclerosis patients. Front Neurol 13:1\u201311","journal-title":"Front Neurol"},{"key":"1866_CR25","doi-asserted-by":"crossref","unstructured":"Miura S, Hiruki S, Okada T, Takei SI, Senzaki K, Okada Y et al (2023) Case report: frontotemporal dementia and amyotrophic lateral sclerosis caused by a missense variant (p.Arg89Trp) in the valosin-containing protein gene. Front Genets 14:1\u20138","DOI":"10.3389\/fgene.2023.1155998"},{"key":"1866_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC et al (2020) Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383:109\u2013119","journal-title":"N Engl J Med"},{"key":"1866_CR27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC et al (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387:1099\u20131110","journal-title":"N Engl J Med"},{"key":"1866_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2017.06.052","volume":"710","author":"EF Smith","year":"2019","unstructured":"Smith EF, Shaw PJ, De Vos KJ (2019) The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett 710:1\u201317","journal-title":"Neurosci Lett"},{"key":"1866_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/hmg\/ddt528","volume":"23","author":"J Magran\u00e9","year":"2014","unstructured":"Magran\u00e9 J, Cortez C, Gan W-B, Manfredi G (2014) Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet 23:1413\u20131424","journal-title":"Hum Mol Genet"},{"key":"1866_CR30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4103\/1673-5374.211179","volume":"12","author":"B Khalil","year":"2017","unstructured":"Khalil B, Li\u00e9vens JC (2017) Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway? Neural Regen Res 12:1052\u20131061","journal-title":"Neural Regen Res"},{"key":"1866_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9041065","volume":"9","author":"M Kodavati","year":"2020","unstructured":"Kodavati M, Wang H, Hegde ML (2020) Altered mitochondrial dynamics in motor neuron disease: an emerging perspective. Cells 9:1\u201323","journal-title":"Cells"},{"key":"1866_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcn.2020.103553","volume":"109","author":"G Lines","year":"2020","unstructured":"Lines G, Casey JM, Preza E, Wray S (2020) Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. Mol Cell Neurosci 109:1\u201323","journal-title":"Mol Cell Neurosci"},{"key":"1866_CR33","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1093\/brain\/awv222","volume":"138","author":"M Iovino","year":"2015","unstructured":"Iovino M, Agathou S, Gonz\u00e1lez-Rueda A, Del Castillo V-H, Borroni B, Alberici A et al (2015) Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain 138:3345\u20133359","journal-title":"Brain"},{"key":"1866_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00911-y","volume":"8","author":"W Guo","year":"2017","unstructured":"Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R et al (2017) HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun 8:1\u201314","journal-title":"Nat Commun"},{"key":"1866_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.2020106177","volume":"40","author":"R Fazal","year":"2021","unstructured":"Fazal R, Boeynaems S, Swijsen A, De Decker M, Fumagalli L, Moisse M et al (2021) HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J 40:1\u201324","journal-title":"EMBO J"},{"key":"1866_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abg3013","volume":"7","author":"L Fumagalli","year":"2021","unstructured":"Fumagalli L, Young FL, Boeynaems S, De Decker M, Mehta AR, Swijsen A et al (2021) C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci Adv 7:1\u201320","journal-title":"Sci Adv"},{"key":"1866_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-016-0316-5","volume":"4","author":"E Onesto","year":"2016","unstructured":"Onesto E, Colombrita C, Gumina V, Borghi MO, Dusi S, Doretti A et al (2016) Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol Commun 4:1\u201314","journal-title":"Acta Neuropathol Commun"},{"key":"1866_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0022-510X(00)00317-8","volume":"176","author":"M Said Ahmed","year":"2000","unstructured":"Said Ahmed M, Hung WY, Zu JS, Hockberger P, Siddique T (2000) Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. J Neurol Sci 176:88\u201394","journal-title":"J Neurol Sci"},{"key":"1866_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.freeradbiomed.2009.11.018","volume":"48","author":"SC Barber","year":"2010","unstructured":"Barber SC, Shaw PJ (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48:629\u2013641","journal-title":"Free Radic Biol Med"},{"key":"1866_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17482960801933942","volume":"9","author":"H Mitsumoto","year":"2008","unstructured":"Mitsumoto H, Santella R, Liu X, Bogdanov M, Zipprich J, Wu HC et al (2008) Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 9:177\u2013183","journal-title":"Amyotroph Lateral Scler"},{"key":"1866_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.stemcr.2015.06.001","volume":"5","author":"M Ehrlich","year":"2015","unstructured":"Ehrlich M, Hallmann AL, Reinhardt P, Ara\u00fazo-Bravo MJ, Korr S, R\u00f6pke A et al (2015) Distinct neurodegenerative changes in an induced pluripotent stem cell model of frontotemporal dementia linked to mutant TAU protein. Stem Cell Rep 5:83\u201396","journal-title":"Stem Cell Rep"},{"key":"1866_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00691318","volume":"55","author":"T Atsumi","year":"1981","unstructured":"Atsumi T (1981) The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis. Acta Neuropathol 55:193\u2013198","journal-title":"Acta Neuropathol"},{"key":"1866_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-4-16","volume":"4","author":"CMJ Higgins","year":"2003","unstructured":"Higgins CMJ, Jung C, Xu Z (2003) ALS-associated mutant SODIG93A causes mitochondrial vacuolation by expansion of the intermembrane space by involvement of SODI aggregation and peroxisomes. BMC Neurosci 4:1\u201314","journal-title":"BMC Neurosci"},{"key":"1866_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/nen.0b013e31802c396b","volume":"66","author":"S Sasaki","year":"2007","unstructured":"Sasaki S, Iwata M (2007) Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 66:10\u201316","journal-title":"J Neuropathol Exp Neurol"},{"key":"1866_CR45","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.neuron.2017.09.055","volume":"96","author":"T Misgeld","year":"2017","unstructured":"Misgeld T, Schwarz TL (2017) Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96:651\u2013666","journal-title":"Neuron"},{"key":"1866_CR46","first-page":"1","volume":"5","author":"TL Schwarz","year":"2013","unstructured":"Schwarz TL (2013) Mitochondrial trafficking in neurons. Cold Spring Harb Perspect Med 5:1\u201316","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1866_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-019-01989-y","volume":"138","author":"CJ Anderson","year":"2019","unstructured":"Anderson CJ, Bredvik K, Burstein SR, Davis C, Meadows SM, Dash J et al (2019) ALS\/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response. Acta Neuropathol 138:103\u2013121","journal-title":"Acta Neuropathol"},{"key":"1866_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2025053118","volume":"118","author":"O Harding","year":"2021","unstructured":"Harding O, Evans CS, Ye J, Cheung J, Maniatis T, Holzbaur ELF (2021) ALS- And FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. Proc Natl Acad Sci USA 118:1\u201311","journal-title":"Proc Natl Acad Sci USA"},{"key":"1866_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2144\/000113610","volume":"50","author":"SW Perry","year":"2011","unstructured":"Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA (2011) Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques 50:98\u2013115","journal-title":"Biotechniques"},{"key":"1866_CR50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0006-3495(99)77239-5","volume":"76","author":"V Petronilli","year":"1999","unstructured":"Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi P et al (1999) Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 76:725\u2013734","journal-title":"Biophys J"},{"key":"1866_CR51","doi-asserted-by":"crossref","unstructured":"Gautier CA, Giaime E, Caballero E, N\u00fa\u0303ez L, Song Z, Chan D et al (2012) Regulation of mitochondrial permeability transition pore by PINK1. Mol Neurodegener 7:1-15","DOI":"10.1186\/1750-1326-7-22"},{"key":"1866_CR52","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1073\/pnas.96.5.2135","volume":"96","author":"A Miyawaki","year":"1999","unstructured":"Miyawaki A, Griesbeck O, Heim R, Tsien RY (1999) Dynamic and quantitative Ca2+ measurements using improved cameleons. Proc Natl Acad Sci 96:2135\u20132140","journal-title":"Proc Natl Acad Sci"},{"key":"1866_CR53","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/embor.2010.115","volume":"11","author":"S Campello","year":"2010","unstructured":"Campello S, Scorrano L (2010) Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep 11:678\u2013684","journal-title":"EMBO Rep"},{"key":"1866_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","volume":"552","author":"LD Zorova","year":"2018","unstructured":"Zorova LD, Popkov VA, Plotnikov EY, Silachev DN, Pevzner IB, Jankauskas SS et al (2018) Mitochondrial membrane potential. Anal Biochem 552:50\u201359","journal-title":"Anal Biochem"},{"issue":"1","key":"1866_CR55","first-page":"1","volume":"2020","author":"E Gnaiger","year":"2020","unstructured":"Gnaiger E et al (2020) Mitochondrial physiology. Bioenerg Commun 2020(1):1\u201344","journal-title":"Bioenerg Commun"},{"key":"1866_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-61779-382-0_11","volume-title":"Mitochondrial bioenergetics: methods and protocol","author":"C Affourtit","year":"2012","unstructured":"Affourtit C, Quinlan CL, Brand MD (2012) Measurement of proton leak and electron leak in isolated mitochondria. In: Palmeira CM, Moreno AJ (eds) Mitochondrial bioenergetics: methods and protocol. Humana Press, Totowa, pp 165\u2013182"},{"key":"1866_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2021.10.014","volume":"177","author":"X-H Lei","year":"2021","unstructured":"Lei X-H, Bochner BR (2021) Optimization of cell permeabilization in electron flow based mitochondrial function assays. Free Radic Biol Med 177:48\u201357","journal-title":"Free Radic Biol Med"},{"key":"1866_CR58","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41418-023-01187-0","volume":"30","author":"P Bernardi","year":"2023","unstructured":"Bernardi P, Gerle C, Halestrap AP, Jonas EA, Karch J, Mnatsakanyan N et al (2023) Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions. Cell Death Differ 30:1869\u20131885","journal-title":"Cell Death Differ"},{"key":"1866_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12091273","volume":"12","author":"R Endlicher","year":"2023","unstructured":"Endlicher R, Drahota Z, \u0160tefkov\u00e1 K, \u010cervinkov\u00e1 Z, Ku\u010dera O (2023) The Mitochondrial permeability transition pore\u2014current knowledge of its structure, function, and regulation, and optimized methods for evaluating its functional state. Cells 12:1\u201317","journal-title":"Cells"},{"key":"1866_CR60","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.yjmcc.2009.02.021","volume":"46","author":"AP Halestrap","year":"2009","unstructured":"Halestrap AP (2009) What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 46:821\u2013831","journal-title":"J Mol Cell Cardiol"},{"key":"1866_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.expneurol.2015.05.010","volume":"271","author":"X Liu","year":"2015","unstructured":"Liu X, Xu S, Wang P, Wang W (2015) Transient mitochondrial permeability transition mediates excitotoxicity in glutamate-sensitive NSC34D motor neuron-like cells. Exp Neurol 271:122\u2013130","journal-title":"Exp Neurol"},{"key":"1866_CR62","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.cell.2020.09.020","volume":"183","author":"CH Yu","year":"2020","unstructured":"Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P et al (2020) TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS\/STING in ALS. Cell 183:636\u2013649","journal-title":"Cell"},{"key":"1866_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/biof.5520080314","volume":"8","author":"V Petronilli","year":"1998","unstructured":"Petronilli V, Miotto G, Canton M, Colonna R, Bernardi P, Di Lisa F (1998) Imaging the mitochondrial permeability transition pore in intact cells. BioFactors 8:263\u2013272","journal-title":"BioFactors"},{"key":"1866_CR64","doi-asserted-by":"crossref","unstructured":"Connern CP, Halestrap AP (1994) Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem J 302(Pt 2):321\u20134","DOI":"10.1042\/bj3020321"},{"key":"1866_CR65","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1093\/hmg\/ddu254","volume":"23","author":"A Zulian","year":"2014","unstructured":"Zulian A, Rizzo E, Schiavone M, Palma E, Tagliavini F, Blaauw B et al (2014) NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models. Hum Mol Genet 23:5353\u20135363","journal-title":"Hum Mol Genet"},{"key":"1866_CR66","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2174\/0929867033457160","volume":"10","author":"PC Waldmeier","year":"2003","unstructured":"Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ (2003) Cyclophilin D as a drug target. Curr Med Chem 10:1485\u20131506","journal-title":"Curr Med Chem"},{"key":"1866_CR67","doi-asserted-by":"publisher","first-page":"9231","DOI":"10.1073\/pnas.87.23.9231","volume":"87","author":"BE Bierer","year":"1990","unstructured":"Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G et al (1990) Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci 87:9231\u20139235","journal-title":"Proc Natl Acad Sci"},{"key":"1866_CR68","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.yjmcc.2009.02.007","volume":"46","author":"CP Baines","year":"2009","unstructured":"Baines CP (2009) The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 46:850\u2013857","journal-title":"J Mol Cell Cardiol"},{"key":"1866_CR69","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.104.075945","volume":"312","author":"AB Reid","year":"2007","unstructured":"Reid AB, Kurten RC, McCullough SS, Bronck RW, Hinson JA (2007) Mechanisms of chloroform-induced hepatotoxicity: oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J Pharmacol Exp Ther 312:509\u2013516","journal-title":"J Pharmacol Exp Ther"},{"key":"1866_CR70","first-page":"95","volume":"36","author":"M Yorimitsu","year":"2004","unstructured":"Yorimitsu M, Muranaka S, Sato EF, Hirofumi F, Kouichi A, Tatsuji Y et al (2004) Role of alpha-tocopherol in the regulation of mitochondrial permeability transition. Physiol Chem Phys Med NMR 36:95\u2013107","journal-title":"Physiol Chem Phys Med NMR"},{"key":"1866_CR71","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1113\/jphysiol.2013.268235","volume":"592","author":"S Marchi","year":"2014","unstructured":"Marchi S, Pinton P (2014) The mitochondrial calcium uniporter complex: molecular components, structure and physiopathological implications. J Physiol 592:829\u2013839","journal-title":"J Physiol"},{"key":"1866_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00259-011-1979-6","volume":"39","author":"A Cistaro","year":"2012","unstructured":"Cistaro A, Valentini MC, Chi\u00f2 A, Nobili F, Calvo A, Moglia C et al (2012) Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging 39:251\u2013259","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1866_CR73","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s00415-009-5100-z","volume":"256","author":"C Bouteloup","year":"2009","unstructured":"Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A et al (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256:1236\u20131242","journal-title":"J Neurol"},{"key":"1866_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2020.117257","volume":"420","author":"P Fayemendy","year":"2021","unstructured":"Fayemendy P, Marin B, Labrunie A, Boirie Y, Walrand S, Achamrah N et al (2021) Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. J Neurol Sci 420:1\u20135","journal-title":"J Neurol Sci"},{"key":"1866_CR75","doi-asserted-by":"crossref","unstructured":"Murali Mahadevan H, Hashemiaghdam A, Ashrafi G, Harbauer AB (2021) Mitochondria in neuronal health: from energy metabolism to Parkinson\u2019s disease. Adv Biol 5:1-18","DOI":"10.1002\/adbi.202100663"},{"key":"1866_CR76","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell 186:693\u2013714","journal-title":"Cell"},{"key":"1866_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2012.115","volume":"3","author":"HZ Yin","year":"2012","unstructured":"Yin HZ, Nalbandian A, Hsu CI, Li S, Llewellyn KJ, Mozaffar T et al (2012) Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis 3:1\u201312","journal-title":"Cell Death Dis"},{"key":"1866_CR78","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/mus.23522","volume":"47","author":"A Nalbandian","year":"2013","unstructured":"Nalbandian A, Llewellyn KJ, Badadani M, Yin HZ, Nguyen C, Katheria V et al (2013) A progressive translational mouse model of human valosin-containing protein disease: the VCPR155H\/+ mouse. Muscle Nerve 47:260\u2013270","journal-title":"Muscle Nerve"},{"key":"1866_CR79","doi-asserted-by":"publisher","first-page":"22360","DOI":"10.1038\/srep22360","volume":"6","author":"T Masuda","year":"2016","unstructured":"Masuda T, Wada Y, Kawamura S (2016) ES1 is a mitochondrial enlarging factor contributing to form mega-mitochondria in zebrafish cones. Sci Rep 6:22360","journal-title":"Sci Rep"},{"key":"1866_CR80","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neuron.2013.02.029","volume":"78","author":"NC Kim","year":"2013","unstructured":"Kim NC, Tresse E, Kolaitis RM, Molliex A, Thomas RE, Alami NH et al (2013) VCP is essential for mitochondrial quality control by PINK1\/Parkin and this function is impaired by VCP mutations. Neuron 78:65\u201380","journal-title":"Neuron"},{"key":"1866_CR81","doi-asserted-by":"publisher","first-page":"25757","DOI":"10.1074\/jbc.M513699200","volume":"281","author":"RJ Braun","year":"2006","unstructured":"Braun RJ, Zischka H, Madeo F, Eisenberg T, Wissing S, Bu S et al (2006) Crucial mitochondrial impairment upon CDC48 mutation in apoptotic yeast. J Biol Chem 281:25757\u201325767","journal-title":"J Biol Chem"},{"key":"1866_CR82","doi-asserted-by":"crossref","unstructured":"Chang YC, Hung WT, Chang YC, Chang HC, Wu CL, Chiang AS et al (2011) Pathogenic VCP\/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a drosophila IBMPFD model. PLoS Genet 7:1-18","DOI":"10.1371\/journal.pgen.1001288"},{"key":"1866_CR83","doi-asserted-by":"publisher","first-page":"8907","DOI":"10.1074\/jbc.M116.762898","volume":"292","author":"MHR Ludtmann","year":"2017","unstructured":"Ludtmann MHR, Arber C, Bartolome F, De Vicente M, Preza E, Carro E et al (2017) Mutations in valosin-containing protein (VCP) decrease ADP\/ATP translocation across the mitochondrial membrane and impair energy metabolism in human neurons. J Biol Chem 292:8907\u20138917","journal-title":"J Biol Chem"},{"key":"1866_CR84","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.celrep.2017.05.024","volume":"19","author":"CE Hall","year":"2017","unstructured":"Hall CE, Yao Z, Choi M, Tyzack GE, Serio A, Luisier R et al (2017) Progressive motor neuron pathology and the role of astrocytes in a human stem cell model of VCP-related ALS. Cell Rep 19:1739\u20131749","journal-title":"Cell Rep"},{"key":"1866_CR85","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2013.02.028","volume":"78","author":"F Bartolome","year":"2013","unstructured":"Bartolome F, Wu HC, Burchell VS, Preza E, Wray S, Mahoney CJ et al (2013) Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron 78:57\u201364","journal-title":"Neuron"},{"key":"1866_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/7821672","volume":"2017","author":"A Ferri","year":"2017","unstructured":"Ferri A, Coccurello R (2017) What is \u201chyper\u201d in the ALS Hypermetabolism? Mediat Inflamm 2017:1\u201311","journal-title":"Mediat Inflamm"},{"key":"1866_CR87","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/jnnp-2017-317887","volume":"89","author":"FJ Steyn","year":"2018","unstructured":"Steyn FJ, Ioannides ZA, Van Eijk RPA, Heggie S, Thorpe KA, Ceslis A et al (2018) Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89:1016\u20131023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1866_CR88","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.1523\/JNEUROSCI.21-17-06608.2001","volume":"21","author":"SA Reichert","year":"2001","unstructured":"Reichert SA, Kim-Han JS, Dugan LL (2001) The mitochondrial permeability transition pore and nitric oxide synthase mediate early mitochondrial depolarization in astrocytes during oxygen-glucose deprivation. J Neurosci 21:6608\u20136616","journal-title":"J Neurosci"},{"issue":"Pt 1","key":"1866_CR89","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1469-7793.2000.00057.x","volume":"529","author":"MR Duchen","year":"2000","unstructured":"Duchen MR (2000) Mitochondria and calcium: from cell signalling to cell death. J Physiol 529(Pt 1):57\u201368","journal-title":"J Physiol"},{"key":"1866_CR90","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.neuron.2016.12.034","volume":"93","author":"A Agarwal","year":"2017","unstructured":"Agarwal A, Wu PH, Hughes EG, Fukaya M, Tischfield MA, Langseth AJ et al (2017) Transient opening of the mitochondrial permeability transition pore induces microdomain calcium transients in astrocyte processes. Neuron 93:587\u2013605","journal-title":"Neuron"},{"key":"1866_CR91","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCRESAHA.115.308093","volume":"118","author":"X Lu","year":"2016","unstructured":"Lu X, Kwong JQ, Molkentin JD, Bers DM (2016) Individual cardiac mitochondria undergo rare transient permeability transition pore openings. Circ Res 118:834\u2013841","journal-title":"Circ Res"},{"key":"1866_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ceca.2014.03.004","volume":"56","author":"E De Marchi","year":"2014","unstructured":"De Marchi E, Bonora M, Giorgi C, Pinton P (2014) The mitochondrial permeability transition pore is a dispensable element for mitochondrial calcium efflux. Cell Calcium 56:1\u201313","journal-title":"Cell Calcium"},{"key":"1866_CR93","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-021-00433-y","volume":"23","author":"M Bonora","year":"2022","unstructured":"Bonora M, Giorgi C, Pinton P (2022) Molecular mechanisms and consequences of mitochondrial permeability transition. Nat Rev Mol Cell Biol 23:266\u2013285","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1866_CR94","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/toxsci\/kfz164","volume":"171","author":"S Stoll","year":"2019","unstructured":"Stoll S, Xi J, Ma B, Leimena C, Behringer EJ, Qin G et al (2019) The valosin-containing protein protects the heart against pathological Ca2+ overload by modulating Ca2+ uptake proteins. Toxicol Sci 171:473\u2013484","journal-title":"Toxicol Sci"},{"key":"1866_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep46324","volume":"7","author":"P Lizano","year":"2017","unstructured":"Lizano P, Rashed E, Stoll S, Zhou N, Wen H, Hays TT et al (2017) The valosin-containing protein is a novel mediator of mitochondrial respiration and cell survival in the heart in vivo. Sci Rep 7:1\u201311","journal-title":"Sci Rep"},{"key":"1866_CR96","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cell.2012.10.011","volume":"151","author":"K Mallilankaraman","year":"2012","unstructured":"Mallilankaraman K, Doonan P, C\u00e1rdenas C, Chandramoorthy HC, M\u00fcller M, Miller R et al (2012) MICU1 is an essential gatekeeper for mcu-mediated mitochondrial Ca2+ uptake that regulates cell survival. Cell 151:630\u2013644","journal-title":"Cell"},{"key":"1866_CR97","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1091\/mbc.E21-03-0097","volume":"32","author":"Y Du","year":"2021","unstructured":"Du Y, Wang J, Xiong J, Fang N, Ji WK (2021) VPS13D interacts with VCP\/p97 and negatively regulates endoplasmic reticulum\u2013mitochondria interactions. Mol Biol Cell 32:1474\u20131486","journal-title":"Mol Biol Cell"},{"key":"1866_CR98","doi-asserted-by":"crossref","unstructured":"Chen J, Bassot A, Giuliani F, Simmen T (2021) Amyotrophic lateral sclerosis (ALS): stressed by dysfunctional mitochondria-endoplasmic reticulum contacts (MERCs). Cells 10:1-20","DOI":"10.3390\/cells10071789"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01866-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-024-01866-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01866-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T21:04:33Z","timestamp":1728594273000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-024-01866-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1186\/s40478-024-01866-0","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"PVD has served in advisory boards for Biogen, CSL Behring (King of Prussia, US), Alexion Pharmaceuticals (Boston, Us), Ferrer (Barcelona, Spain), QurAlis (Cambridge, UK), Cytokinetics (South San Francisco, US), Argenx (Boston, US), UCB (Brussels, Belgium), Muna Therapeutics, Alector (South San Francisco, US), Augustine Therapeutics (Leuven, Belgium), VectorY (Amsterdam, Netherlands), Zambon (Bresso, Italy), Amylyx (Cambridge, UK) (paid to institution). P.V.D. has received speaker fees from Biogen and Amylyx (paid to institution). PVD is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders (from CSL Behring, paid to institution). ED, KP and\u00a0MF own reMYND warrants. GG is a consultant for reMYND and owns reMYND warrants and shares. LVDB is head of the Scientific Advisory Board of Augustine Therapeutics and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium). LVDB is a scientific founder of Augustine Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}